Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A414BN | ISIN: US47010C8881 | Ticker-Symbol: 1JA0
NASDAQ
05.06.25 | 17:25
4,000 US-Dollar
+1,52 % +0,060
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
JAGUAR HEALTH INC Chart 1 Jahr
5-Tage-Chart
JAGUAR HEALTH INC 5-Tage-Chart

Aktuelle News zur JAGUAR HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.05.Jaguar Health, Inc. - 8-K, Current Report20
21.05.Jaguar Health Stock Falls 23% Following $1.5 Mln Direct Offering Announcement4
21.05.Jaguar Health kündigt Direktplatzierung in Höhe von 1,5 Millionen US-Dollar an24
21.05.Jaguar Health announces $1.5 million direct offering2
21.05.Jaguar Health, Inc.: Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules207SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and...
► Artikel lesen
20.05.Jaguar Health, Inc.: First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease245As announced, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient...
► Artikel lesen
19.05.Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Initiation of Coverage Recommendation - Buy325Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH 19.05.2025 / 16:37 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
16.05.Jaguar Health outlines rare disease catalyst convergence and expedited regulatory pathways for crofelemer following proof-of-concept results6
JAGUAR HEALTH Aktie jetzt für 0€ handeln
15.05.Jaguar Health, Inc.: Jaguar Health Reports First Quarter 2025 Financials289The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4...
► Artikel lesen
15.05.Jaguar Health, Inc. - 10-Q, Quarterly Report4
14.05.Jaguar Health, Inc.: Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates264Click here to registerCompany plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025 SAN FRANCISCO, CA / ACCESS Newswire / May 14, 2025 / Jaguar Health,...
► Artikel lesen
09.05.Jaguar Health, Inc. - 8-K, Current Report5
08.05.Jaguar Health, Inc.: Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs321Company's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment...
► Artikel lesen
07.05.Jaguar Health, Inc.: Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts601Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical GuidanceClick here to access replay of company's April 30, 2025 investor webcast SAN FRANCISCO...
► Artikel lesen
30.04.Jaguar Health meldet vielversprechende Ergebnisse für Crofelemer bei seltenen Krankheiten12
30.04.Jaguar Health, Inc.: Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease and Short Bowel Syndrome with Intestinal Failure by up to 27% and 12.5% - Potential to Modify Dis252Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI...
► Artikel lesen
29.04.Jaguar Health, Inc.: REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease and Short Bowel Syndrome with Intestinal Failure299The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for...
► Artikel lesen
28.04.Jaguar Health, Inc.: Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease and Short Bowel Syndrome with Intestinal Failure During an April 30 Investor Webcast154The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for...
► Artikel lesen
28.04.Jaguar Health, Inc. - 8-K, Current Report3
19.04.Jaguar Health, Inc. - 8-K, Current Report3
Seite:  Weiter >>
115 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1